167 related articles for article (PubMed ID: 21417902)
1. Metronomic scheduling of anticancer treatment: the next generation of multitarget therapy?
André N; Padovani L; Pasquier E
Future Oncol; 2011 Mar; 7(3):385-94. PubMed ID: 21417902
[TBL] [Abstract][Full Text] [Related]
2. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
Shapira A; Livney YD; Broxterman HJ; Assaraf YG
Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
[TBL] [Abstract][Full Text] [Related]
3. Metronomic scheduling: the future of chemotherapy?
Gasparini G
Lancet Oncol; 2001 Dec; 2(12):733-40. PubMed ID: 11902515
[TBL] [Abstract][Full Text] [Related]
4. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors.
Folkins C; Man S; Xu P; Shaked Y; Hicklin DJ; Kerbel RS
Cancer Res; 2007 Apr; 67(8):3560-4. PubMed ID: 17440065
[TBL] [Abstract][Full Text] [Related]
5. Low-dose metronomic chemotherapy: from past experience to new paradigms in the treatment of cancer.
Loven D; Hasnis E; Bertolini F; Shaked Y
Drug Discov Today; 2013 Feb; 18(3-4):193-201. PubMed ID: 22868084
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy.
Drevs J; Fakler J; Eisele S; Medinger M; Bing G; Esser N; Marmé D; Unger C
Anticancer Res; 2004; 24(3a):1759-63. PubMed ID: 15274352
[TBL] [Abstract][Full Text] [Related]
7. Tumor microenvironment and therapeutic response.
Wu T; Dai Y
Cancer Lett; 2017 Feb; 387():61-68. PubMed ID: 26845449
[TBL] [Abstract][Full Text] [Related]
8. Metronomic chemotherapy: Back to the future!
André N; Padovani L; Verschuur A
Drug News Perspect; 2010 Mar; 23(2):143-51. PubMed ID: 20369080
[TBL] [Abstract][Full Text] [Related]
9. Dynamical properties of a minimally parameterized mathematical model for metronomic chemotherapy.
Schättler H; Ledzewicz U; Amini B
J Math Biol; 2016 Apr; 72(5):1255-80. PubMed ID: 26089097
[TBL] [Abstract][Full Text] [Related]
10. Tumor endothelial cells as a potential target of metronomic chemotherapy.
Kim JY; Kim YM
Arch Pharm Res; 2019 Jan; 42(1):1-13. PubMed ID: 30604201
[TBL] [Abstract][Full Text] [Related]
11. Metronomic chemotherapy for cancer treatment: a decade of clinical studies.
Romiti A; Cox MC; Sarcina I; Di Rocco R; D'Antonio C; Barucca V; Marchetti P
Cancer Chemother Pharmacol; 2013 Jul; 72(1):13-33. PubMed ID: 23475105
[TBL] [Abstract][Full Text] [Related]
12. Metronomic chemotherapy from rationale to clinical studies: a dream or reality?
Gnoni A; Silvestris N; Licchetta A; Santini D; Scartozzi M; Ria R; Pisconti S; Petrelli F; Vacca A; Lorusso V
Crit Rev Oncol Hematol; 2015 Jul; 95(1):46-61. PubMed ID: 25656744
[TBL] [Abstract][Full Text] [Related]
13. Can targeted therapy be successful without metronomic scheduling?
André N; Pasquier E; Kamen B
Curr Top Med Chem; 2012; 12(15):1639-42. PubMed ID: 22978340
[TBL] [Abstract][Full Text] [Related]
14. Metronomic dosing of chemotherapy: applications in pediatric oncology.
Stempak D; Seely D; Baruchel S
Cancer Invest; 2006; 24(4):432-43. PubMed ID: 16777697
[TBL] [Abstract][Full Text] [Related]
15. License for destruction: tumor-specific cytokine targeting.
Johansson A; Hamzah J; Ganss R
Trends Mol Med; 2014 Jan; 20(1):16-24. PubMed ID: 24169116
[TBL] [Abstract][Full Text] [Related]
16. Strategy for the development of novel anticancer drugs.
Saijo N; Tamura T; Nishio K
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S97-101. PubMed ID: 12856152
[TBL] [Abstract][Full Text] [Related]
17. Assessing the in vivo efficacy of biologic antiangiogenic therapies.
Wilson PM; LaBonte MJ; Lenz HJ
Cancer Chemother Pharmacol; 2013 Jan; 71(1):1-12. PubMed ID: 23053262
[TBL] [Abstract][Full Text] [Related]
18. Autophagy: shaping the tumor microenvironment and therapeutic response.
Maes H; Rubio N; Garg AD; Agostinis P
Trends Mol Med; 2013 Jul; 19(7):428-46. PubMed ID: 23714574
[TBL] [Abstract][Full Text] [Related]
19. Drug development for cancer chemoprevention: focus on molecular targets.
Johnson KA; Brown PH
Semin Oncol; 2010 Aug; 37(4):345-58. PubMed ID: 20816505
[TBL] [Abstract][Full Text] [Related]
20. Restriction of drug transport by the tumor environment.
Nandigama R; Upcin B; Aktas BH; Ergün S; Henke E
Histochem Cell Biol; 2018 Dec; 150(6):631-648. PubMed ID: 30361778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
